Actively Recruiting
MRD Response-adapted Allo-HSCT for Adverse-risk AML
Led by Peking University People's Hospital · Updated on 2024-07-10
178
Participants Needed
1
Research Sites
205 weeks
Total Duration
On this page
Sponsors
P
Peking University People's Hospital
Lead Sponsor
R
Ruijin Hospital
Collaborating Sponsor
AI-Summary
What this Trial Is About
This TROPHY-AML01 regimen aims to identify the effectiveness and safety of MRD response-adapted allo-HSCT for adverse-risk acute myeloid leukemia in an open-label, randomized, controlled trial.
CONDITIONS
Official Title
MRD Response-adapted Allo-HSCT for Adverse-risk AML
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Newly diagnosed acute myeloid leukemia
- Classified as adverse-risk group according to ELN 2022 criteria
- Age between 16 and 65 years at diagnosis
- Achieved complete remission after 1 or 2 courses of induction chemotherapy
- Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 1
- Signed informed consent by patient or legal guardian
You will not qualify if you...
- AML classified as favorable- or intermediate-risk according to ELN 2022 criteria
- Younger than 16 or older than 65 years at diagnosis
- Achieved complete remission only after 3 or more courses of induction chemotherapy or unable to achieve remission
- ECOG performance status score of 2 or higher
- Other medical or mental conditions that affect safety, consent, compliance, or follow-up
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Peking University People's Hospital
Beijing, China
Actively Recruiting
Research Team
X
Xiaodong Mo
CONTACT
X
Xiaoxia Hu
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here